Real–life observational cohort “TOPASE” subgroup analysis highlights efficacy of ponatinib to maintain or induce a deep molecular response in CP-CML patients

Authors
Publication date
1 January 2021
Publisher
HAL CCSD

Abstract

International audienc

    Similar works

    Full text

    thumbnail-image

    Available Versions

    HAL Clermont Université

    redirect
    oaioai:HAL:hal-03462869v1
    Last time updated on 26/12/2021

    HAL-Inserm

    redirect
    oaioai:HAL:hal-03462869v1
    Last time updated on 27/12/2021